Functional Impairment of Human Resident Cardiac Stem Cells by the Cardiotoxic Antineoplastic Agent Trastuzumab

Trastuzumab (TZM), a monoclonal antibody against the ERBB2 protein, increases survival in ERBB2-positive breast cancer patients. Its clinical use, however, is limited by cardiotoxicity. We sought to evaluate whether TZM cardiotoxicity involves inhibition of human adult cardiac-derived stem cells, in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Barth, Andreas S., Zhang, Yiqiang, Li, Taosheng, Smith, Rachel R., Chimenti, Isotta, Terrovitis, Ioannis, Davis, Darryl R., Kizana, Eddy, Ho, Alice S., O'Rourke, Brian, Wolff, Antonio C., Gerstenblith, Gary, Marbán, Eduardo
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2012
Matèries:
Original Articles and Reviews
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3659699/
https://ncbi.nlm.nih.gov/pubmed/23197808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5966/sctm.2011-0016
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars